BACK

Lung Trials

Clinical trial information


Select trial for more information

Area under investigation=true,EGFRm NSCLC,Mesothelioma,MET-driven NSCLC,NSCLC,SCLC

ADAURA2 trial overview

Tumor

EGFRm Stage IA2-IA3 NSCLC following complete tumor resection

Trial Identifier

NCT05120349

Phase

III

Stage

Resectable Stage I-III

Regimen

Osimertinib; placebo

Visit ct.gov
Go

ADRIATIC trial overview

Tumor

Limited stage SCLC not progressed following cCRT

Trial Identifier

NCT03703297

Phase

III

Regimen

Durvalumab; durvalumab + tremelimumab; placebo

Visit ct.gov
Go

ALTAIR trial overview

Tumor

Advanced or metastatic squamous or non-squamous NSCLC

Trial Identifier

NCT06996782

Phase

Ib/II

Stage

Stage IV

Regimen

Rilvegostomig + ramucirumab + PBC (squamous histology); rilvegostomig + ramucirumab + chemotherapy OR rilvegostomig + chemotherapy (for non-squamous histology)

Visit ct.gov
Go

ARTEMIDE-01 trial overview

Tumor

Advanced or metastatic NSCLC, 1L/2L

Trial Identifier

NCT04995523

Phase

I/II

Stage

Metastatic, ≥1L

Regimen

Rilvegostomig

Visit ct.gov
Go

ARTEMIDE-Lung02 trial overview

Tumor

Advanced or metastatic squamous NSCLC, 1L

Trial Identifier

NCT06692738

Phase

III

Stage

Metastatic, 1L

Regimen

Rilvegostomig + platinum based CT; pembrolizumab + platinum-based CT

Visit ct.gov
Go

ARTEMIDE-Lung03 trial overview

Tumor

Advanced or metastatic non-squamous NSCLC, 1L

Trial Identifier

NCT06627647

Phase

III

Stage

Metastatic, 1L

Regimen

Rilvegostomig + platinum based doublet CT; pembrolizumab + platinum-based doublet CT

Visit ct.gov
Go

ARTEMIDE-Lung04 trial overview

Tumor

Advanced or metastatic NSCLC, 1L

Trial Identifier

NCT06868277

Phase

III

Stage

Metastatic, 1L

Regimen

Rilvegostomig; pembrolizumab

Visit ct.gov
Go

AVANZAR trial overview

Tumor

Advanced/metastatic NSCLC without actionable genomic alterations

Trial Identifier

NCT05687266

Phase

III

Stage

Advanced/metastatic NSCLC, 1L

Regimen

Dato-DXd + durvalumab + carboplatin; histologic-specific therapy (pembrolizumab + CT)

Visit ct.gov
Go

DESTINY-Lung03 trial overview

Tumor

Unresectable locally advanced/metastatic non-squamous HER2 overexpressing NSCLC

Trial Identifier

NCT04686305

Phase

Ib

Stage

Metastatic, ≥1L

Regimen

T-DXd + durvalumab + (cisplatin/carboplatin/pemetrexed); T-DXd; T-DXd + volrustomig ± carboplatin; T-DXd + rilvegostomig ± carboplatin

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

DESTINY-Lung04 trial overview

Tumor

Unresectable, locally advanced, or metastatic NSCLC with HER2 Exon 19 or 20 mutations

Trial Identifier

NCT05048797

Phase

III

Stage

Metastatic, 1L

Regimen

T-DXd; SoC (cisplatin or carboplatin + pemetrexed + pembrolizumab)

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

DESTINY-Lung06 trial overview

Tumor

Locally advanced unresectable, or metastatic HER2 overexpressing and PD-L1 TPS <50% nonsquamous NSCLC

Trial Identifier

NCT06899126

Phase

III

Regimen

T-DXd + pembrolizumab; pembrolizumab + pemetrexed + platinum-based chemotherapy (cisplatin or carboplatin)

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

DS8201-A-U106 trial overview

Tumor

Locally advanced/metastatic HER2-positive breast cancer (as per ASCO-CAP guidelines), HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-), HER2-expressing NSCLC (IHC 1+, 2+, or 3+), and HER2-mutant NSCLC

Trial Identifier

NCT04042701

Phase

Ib

Regimen

T-DXd + pembrolizumab

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

eVOLVE-01 trial overview

Tumor

NSCLC

Trial Identifier

NCT06448754

Phase

II

Regimen

Volrustomig (different doses) + chemotherapy; volrustomig + ramucirumab + chemotherapy

Visit ct.gov
Go

eVOLVE-02 trial overview

Tumor

Advanced or metastatic tumors (Cervical, HNSCC, pleural mesothelioma, and ESCC)

Trial Identifier

NCT06535607

Phase

II

Regimen

Volrustomig monotherapy; volrustomig + chemotherapy

Visit ct.gov
Go

eVOLVE-Meso trial overview

Tumor

Advanced unresectable pleural mesothelioma

Trial Identifier

NCT06097728

Phase

III

Regimen

Volrustomig + carboplatin + pemetrexed; investigator's choice of standard care

Visit ct.gov
Go

FONTANA trial overview

Tumor

Advanced solid tumors

Trial Identifier

NCT05797168

Phase

I/IIa

Regimen

Torvutatug samrotecan monotherapy; torvutatug samrotecan + saruparib; torvutatug samrotecan + bevacizumab; torvutatug samrotecan + carboplatin ± bevacizumab; torvutatug samrotecan + palacaparib

Visit ct.gov
Go

LIBRA trial overview

Tumor

Locally advanced/metastatic NSCLC

Trial Identifier

NCT07098338

Phase

II

Stage

Stage IV

Regimen

Rilvegostomig ± ramucirumab; Dato‑DXd + ramucirumab ± rilvegostomig

Visit ct.gov
Go

NeoADAURA trial overview

Tumor

EGFRm resectable stage II-IIIB N2 NSCLC

Trial Identifier

NCT04351555

Phase

III

Stage

Resectable Stage II-III

Regimen

Osimertinib; PtCh ± osimertinib

Visit ct.gov
Go

NeoCOAST-2 trial overview

Tumor

Resectable stage IIA to IIIB NSCLC (EGFR/ALK wild-type)

Trial Identifier

NCT05061550

Phase

II

Stage

Resectable disease (IIA to IIIB)

Regimen

Oleclumab + durvalumab + PtCh; monalizumab + durvalumab + PtCh; volrustomig (dose exploration) + PtCh; Dato-DXd + durvalumab + single agent platinum; AZD0171 + durvalumab + PtCh; rilvegostomig + PtCh; Dato-DXd + rilvegostomig + single agent platinum

Visit ct.gov
Go

ORCHARD trial overview

Tumor

Advanced/metastatic EGFRm NSCLC with disease progression following 1L therapy with osimertinib

Trial Identifier

NCT03944772

Phase

II

Stage

Advanced/metastatic NSCLC

Regimen

Osimertinib + (savolitinib or gefitinib or necitumumab or alectinib or selpercatinib or pemetrexed + PtCh or selumetinib or Dato-DXd); durvalumab + pemetrexed + carboplatin; durvalumab + etoposide + PtCh

Visit ct.gov
Go

PACIFIC-4 trial overview

Tumor

Unresected Stage I/II, lymph node-negative NSCLC including tumors harboring a sensitizing EGFR mutation

Trial Identifier

NCT03833154

Phase

III

Stage

Unresected Stage I-II

Regimen

SBRT + placebo; SBRT + durvalumab; SBRT followed by osimertinib

Visit ct.gov
Go

PACIFIC-9 trial overview

Tumor

Unresectable stage III NSCLC not progressed following definitive platinum-based cCRT

Trial Identifier

NCT05221840

Phase

III

Stage

Unresectable Stage III

Regimen

Durvalumab + oleclumab; durvalumab + monalizumab; durvalumab + placebo

Visit ct.gov
Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

SAFFRON trial overview

Tumor

Locally advanced or metastatic EGFRm, MET overexpressed and/or amplified (IHC3+/≥90% and/or FISH10+) NSCLC that progressed on 1L or 2L osimertinib therapy

Trial Identifier

NCT05261399

Phase

III

Stage

Metastatic, ≥2L

Regimen

Osimertinib + savolitinib; pemetrexed + PtCh

Visit ct.gov

Savolitinib, partnered with HUTCHMED

Go

SAVANNAH trial overview

Tumor

EGFRm and MET overexpressed and/or amplified (IHC3+/≥90% and/or FISH10+), locally advanced or metastatic NSCLC that progressed following 1L osimertinib treatment

Trial Identifier

NCT03778229

Phase

II

Stage

Metastatic, ≥2L

Regimen

Osimertinib + savolitinib; placebo + savolitinib

Visit ct.gov

Savolitinib, partnered with HUTCHMED

Go

TROPION-Lung04 trial overview

Tumor

Advanced/metastatic NSCLC without actionable genomic alterations and with/without previous treatment

Trial Identifier

NCT04612751

Phase

Ib

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd + durvalumab ± carboplatin; Dato-DXd + rilvegostomig ± carboplatin; Dato-DXd + sabestomig

Visit ct.gov
Go

TROPION-Lung07 trial overview

Tumor

Treatment-naïve patients with nonsquamous advanced/metastatic NSCLC without actionable genomic alterations and PD-L1 TPS <50%

Trial Identifier

NCT05555732

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd + pembrolizumab ± PtCh; pembrolizumab + pemetrexed + PtCh

Visit ct.gov

This study is sponsored by Daiichi Sankyo, Inc.

Go

TROPION-Lung08 trial overview

Tumor

Treatment naive patients with advanced/metastatic NSCLC without actionable genomic alterations and with high PD-L1 expression (TPS ≥50%)

Trial Identifier

NCT05215340

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd + pembrolizumab; pembrolizumab

Visit ct.gov

This study is sponsored by Daiichi Sankyo, Inc.

Go

TROPION-Lung10 trial overview

Tumor

Advanced/metastatic nonsquamous NSCLC without actionable genomic alterations and with high PD-L1 expression (TC ≥ 50%), 1L

Trial Identifier

NCT06357533

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd + rilvegostomig; rilvegostomig; pembrolizumab

Visit ct.gov
Go

TROPION-Lung14 trial overview

Tumor

Advanced/metastatic, or recurrent, EGFRm (Ex19del and/or L858R) nonsquamous NSCLC, 1L

Trial Identifier

NCT06350097

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Osimertinib + Dato-DXd; osimertinib

Visit ct.gov
Go

TROPION-Lung15 trial overview

Tumor

Advanced/metastatic EGFRm NSCLC with disease progression on prior osimertinib therapy

Trial Identifier

NCT06417814

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd + osimertinib; Dato-DXd; pemetrexed + carboplatin or cisplatin followed by pemetrexed

Visit ct.gov
Go

TROPION-Lung17 trial overview

Tumor

TROP2 NMR positive advanced/metastatic nonsquamous NSCLC without actionable genomic alterations

Trial Identifier

NCT07291037

Phase

III

Stage

Advanced/metastatic NSCLC

Regimen

Dato-DXd; docetaxel

Visit ct.gov
Go

TROPION-PanTumor01 trial overview

Tumor

Advanced solid tumors including advanced/metastatic NSCLC, TNBC, HR-positive/HER2-negative breast cancer, HER2-low breast cancer, and other solid tumors

Trial Identifier

NCT03401385

Phase

I

Regimen

Dato-DXd

Visit ct.gov

This study is sponsored by Daiichi Sankyo, Inc.

Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.